AllSci News
MapLight's M1/M4 agonist aces Phase II schizophrenia trial
MapLight Therapeutics (Nasdaq: MPLT) reported positive topline results from its Phase II ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of...
Apnimed seeks USD 150m IPO ahead of February 2027 FDA decision on sleep apnea drug
Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based company whose sole clinical asset is an NDA-stage oral therapy for obstructive sleep apnea...
Gossamer reacquires seralutinib rights ahead of September NDA submission in PAH
Gossamer Bio (Nasdaq: GOSS) announced on July 27 that FDA meeting minutes from a mid-June Pre-NDA Type B meeting support a September 2026 NDA submission for...
InnoCare's oral TYK2 meets primary endpoint in Phase III psoriasis trial
InnoCare Pharma (HKEX: 09969; SSE: 688428) announced that fadeucravacitinib, its oral TYK2 inhibitor, met the primary endpoint with statistical significance...
Einstein College of Medicine receives USD 13.8m NIAID grant for rapid-response viral vaccine platform
Albert Einstein College of Medicine has received a USD 13.8 million NIAID U19 cooperative agreement to lead PROVIDENT, a 13-institution consortium...
Feinstein Institutes releases comprehensive vagus nerve atlas from 30 donors, advancing bioelectronic medicine device design
Researchers at the Feinstein Institutes for Medical Research, the research arm of Northwell Health in Manhasset, New York, have released the most detailed...
Roche Q2'26: Divarasib outlook rises after Phase III win as obesity pipeline advances
Roche's Q2 2026 earnings call, held on July 23, 2026, was dominated by a positive Phase III readout for divarasib in KRAS G12C-positive non-small cell lung...
FDA briefing casts doubt on Capricor's deramiocel ahead of DMD advisory committee
San Diego-based Capricor Therapeutics (Nasdaq: CAPR) faces a critical regulatory test on Tuesday when the US FDA's Cellular, Tissue, and Gene Therapies...
Revagenix opens first clinical trial of LpxC inhibitor for Pseudomonas-driven bronchiectasis
San Francisco-based Revagenix, Inc. has dosed the first participant in a Phase I trial of Rev-56, an inhaled therapy targeting chronic Pseudomonas...
CAMP4 launches first-in-human trial of antisense therapy for SYNGAP1 disorder in Australia
Cambridge, Massachusetts-based CAMP4 Therapeutics Corporation (Nasdaq: CAMP) has received clearance from Australia's Therapeutic Goods Administration (TGA)...
NIH backs MD Anderson with USD 3m grant to validate tumor prediction NAMs in CRC trials
The University of Texas MD Anderson Cancer Center has received a USD 3 million NIH cooperative agreement to validate predictive tumor models — combining in...
Isoprene advances AR-V7-targeting molecular glue degrader with NCI funding
Baltimore-based Isoprene Pharmaceuticals, Inc. has received a USD 1.02 million NCI SBIR R44 grant to complete IND-enabling preclinical studies for...
Entera Bio raises USD 275m to fund Phase III trial of oral osteoporosis therapy EB613
Israel-based Entera Bio Ltd. (Nasdaq: ENTX) announced an oversubscribed private placement of approximately USD 275 million to fully fund the Phase III...
RA Capital-backed Oak Hill to go public in USD 175m SPAC deal
Cambridge, Massachusetts-based Oak Hill Bio has agreed to merge with Research Alliance Corporation III (Nasdaq: RACC), a special purpose acquisition company...
Bio-Thera advances CD25-targeted ADC into first human trial for solid tumors.
Bio-Thera Solutions, Ltd. (SH: 688177), a Guangzhou, China-based commercial-stage pharmaceutical company, has dosed the first patient in a Phase I trial of...
The AllSci Brief
Free, systematic R&D and deal news. Daily.